According to a recent LinkedIn post from Cagent Vascular Inc, Dr. Frank Arko presented at the Charing Cross Symposium 2026 on the challenge of elastic recoil in peripheral arterial disease (PAD). The post highlights Serration Remodeling Therapy (SRT) as helping define a potential new standard of care aimed at delivering more predictable and durable patient outcomes.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Cagent Vascular’s SRT platform is being positioned within leading international vascular and endovascular forums, which may support physician awareness and clinical adoption. For investors, stronger clinical mindshare in PAD could translate into increased procedure volumes over time, potentially enhancing revenue prospects and reinforcing the company’s niche position in the vascular intervention market.